Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-11-07
2009-12-15
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S450000, C514S456000, C549S407000, C549S355000, C549S467000, C544S153000, C546S284100
Reexamination Certificate
active
07632861
ABSTRACT:
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
REFERENCES:
patent: 5620989 (1997-04-01), Harrison et al.
patent: 5760018 (1998-06-01), Baker et al.
patent: 7098203 (2006-08-01), Wu et al.
patent: 7138423 (2006-11-01), Wu et al.
patent: 7276631 (2007-10-01), Wu et al.
patent: 7494986 (2009-02-01), Wu et al.
patent: 2006/0223830 (2006-10-01), De Nanteuil et al.
patent: 2007/0249607 (2007-10-01), Degnan et al.
patent: 2008/0027056 (2008-01-01), Parker et al.
patent: 2009/0018132 (2009-01-01), Degnan et al.
patent: 2009/0018163 (2009-01-01), Schmitz et al.
patent: WO 03/078376 (2003-09-01), None
patent: WO 2004/004722 (2004-01-01), None
patent: WO 2004/022539 (2004-03-01), None
Gentsch, C. et al., “Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils”, Behavioural Brain Research, vol. 133, pp. 363-368 (2002).
Kramer, M.S. et al., “Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors”, Science, vol. 281, pp. 1640-1645 (1998).
Papp, M. et al., “The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats”, Behavioural Brain Research, vol. 115, pp. 19-23 (2000).
Rosen, T.J. et al., “Synthesis and Structure-Activity Relationships of CP-122,721, a Second-Generation NK-1 Receptor Antagonist”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 281-284 (1998).
Stevenson, G.I. et al., “4,4-Disubstituted Piperidine High-Affinity NK1Antagonists: Structure-Activity Relationships and in Vivo Activity”, Journal of Medicinal Chemistry, vol. 41, No. 23, pp. 4623-4635 (1998).
Stevenson, G.I. et al., “4,4-Disubstituted Piperidines: A New Class of NK1Antagonist”, Journal of Medicinal Chemistry, vol. 38, No. 8, pp. 1264-1266 (1995).
Varty, G.B. et al., “The Gerbil Elevated Plus-maze II: Anxiolytic-like Effects of Selective Neurokinin NK1 Receptor Antagonists”, Neuropsychopharmacology, vol. 27, No. 3, pp. 371-379 (2002).
Bronson Joanne J.
Degnan Andrew P.
Schmitz William D.
Bristol--Myers Squibb Company
Dentz Bernard
Epperson James
Gallis David E
LandOfFree
Substituted heterocyclic ethers and their use in CNS disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic ethers and their use in CNS disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic ethers and their use in CNS disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103451